This study investigated risk factors for atherosclerosis and their relationship with lesion sites. Patients (n = 160) with peripheral artery disease (PAD) completed a questionnaire regarding risk factors for PAD. Endothelial nitric oxide synthase (eNOS) and interleukin (IL)-6 gene polymorphisms and asymmetric dimethylarginine (ADMA) levels were measured. Patients with coronary artery disease had significantly higher ratios of eNOS T/C and C/C genotypes, which include the C allele, than the T/T genotype. The IL-6 gene polymorphism distribution ratios for patients with over four risk factors were significantly different compared with other patients, with a higher rate of the C/C genotype. ADMA levels did not show any significant relationship to risk factors or polymorphism. Levels were, however, slightly higher in femoral lesion sites. The results support a model in which the C/C genotype of eNOS and IL-6 gene polymorphisms promote PAD development. The eNOS C/C genotype may have an independent effect, whereas the effects of the IL-6 C/C genotype are seen in conjunction with other risk factors.
Introduction
Atherosclerosis is a complex, multifactorial disease caused by the interaction of environmental factors and genetic components from many biological pathways, each component adding an increased risk of disease development. 1 The common atherosclerotic risk factors, diabetes mellitus (DM), hypertension and smoking, are related to vascular dysfunction with underlying monocyte adhesion and invasion, smooth muscle proliferation and AK Tuygun, M Keser, A Tuygun et al.
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migration, platelet activation, and extracellular matrix formation. 2 Indirect evidence suggests that alterations in the nitric oxide (NO) pathway might lead to endothelial dysfunction and atherosclerosis. In particular, NO produced by NO synthase (NOS) in the vascular endothelium affects blood flow, blood pressure, platelets, and vascular smooth muscle and endothelial cells. 2, 3 Endothelium-derived NO is synthesized from L-arginine by endothelial NOS (eNOS), which is encoded by the NOS3 gene on chromosome 7. 4 NO-mediated endothelial function is deficient in pre-atherosclerotic states and correlates with risk factor profile. 5 The important role of NO in vascular disease pathogenesis has been demonstrated by numerous animal model studies. Targeted deletion of the eNOS gene in mice results in hypertension and impaired vascular remodelling, whereas augmenting NO by local gene delivery of NOS improves endothelial function, limits neointimal proliferation and induces regression of atherosclerotic lesions. 6 Asymmetric dimethylarginine (ADMA) is a naturally occurring amino acid resulting from proteolysis of methylated arginine residues in proteins. Since the first discovery as an endogenous inhibitor by Vallance et al. 7 in 1992, the significant role of ADMA in endothelial dysfunction has been described in various pathological conditions, including atherosclerosis. 8, 9 A high concentration of plasma ADMA has been associated with several risk factors for atherosclerosis and elevated risk for acute coronary events. 10, 11 A study showed that plasma ADMA concentrations in patients who were newly diagnosed with acute coronary syndromes were higher than in age-matched healthy control subjects. 12 The mechanism of elevation of ADMA plasma concentration in atherosclerosis is not yet clear.
Type 1 protein arginine methyltransferase, which catalyses the methylation of arginine, is expressed in vascular endothelial cells and is upregulated by low-density lipoproteins. 13, 14 Dimethylarginine dimethylaminohydrolase (DDAH) metabolizes 90% of ADMA. 15 DDAH can be inhibited by nitrosation caused by a potent oxidant, peroxynitrate, under highoutput NO production from eNOS expression, e.g. under the condition of atherosclerosis, leading to ADMA accumulation. In the presence of high concentrations of ADMA, eNOS produces superoxide instead of NO, which leads to further oxidation of DDAH and further accumulation of ADMA. 16 Interleukin-6 (IL-6) is a multifunctional cytokine that has a major role in driving the acute inflammatory response and it induces the expression of acute phase inflammatory proteins, including fibrinogen and C-reactive protein (CRP). 17 There have been several reports on the relationships between IL-6 gene polymorphisms and CRP. Although it has been reported that the presence of the C allele of the G(−174)C polymorphism was significantly associated with higher CRP concentrations in hypertensive patients, 18 another study found no significant association of the G(−174)C polymorphism with CRP concentration in patients with coronary artery disease (CAD). 19 In contrast, it has been reported that there is a significant association of the -174G allele with increased levels of CRP in patients with type 2 diabetes. 20 These inconclusive results suggest that the G(−174)C polymorphism may influence underlying diseases and conditions.
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ADMA LEVELS
For measurement of ADMA levels, after 12 h of fasting, venous blood samples were collected in Vacutainer ® tubes (BD Vacutainer Systems, Preanalytical Solutions, Plymouth, UK) with K3-ethylenediaminetetraacetic acid (1/10 v/v) as an anticoagulant. Samples were centrifuged immediately at 3000 g for 15 min to separate the plasma, which was then kept at -20°C until analysis. Lipaemic and haemolytic specimens were discarded. The ADMA analysis was performed using an immunodiagnostic ADMA enzyme-linked immunosorbent assay (ELISA) kit (DLD Diagnostika, Hamburg, Germany).
GENE POLYMORPHISM
To determine IL-6 and eNOS gene polymorphism, genomic DNA was extracted from peripheral lymphocytes as previously described. 21, 22 eNOS gene polymorphism analysis Polymerase chain reaction (PCR) was carried out in a thermal cycler using oligonucleotide primers 5′-TGGAGAGTGCTGGTGTACCCCA-3′ (forward) and 5′-GCCTCCACCCCCACCCT GTC-3′ (reverse). After 4 min of denaturation at 94°C, 35 cycles were performed, each consisting of 30 s at 94°C for denaturation, 30 s at 65°C for annealing and 60 s at 72°C for extension. In the last cycle, the elongation time was prolonged to 5 min. The PCR product was digested with 10 U MspI restriction enzyme (MBI Fermantas, Hanover, MD, USA) at 37°C overnight, producing fragments of 140 and 40 base pairs (bp) for the wild type allele (allele T), or 90, 50 and 40 bp in the case of a polymorphic variant (allele C) for restriction fragment length polymorphism (RFLP). After digestion, the fragments were run in 3% agarose gel electrophoresis and visualized with ethidium bromide under ultraviolet light.
IL-6 gene polymorphism analysis
DNA was extracted from cellular blood components by the salting-out method. 23 PCR was used to detect the IL-6 SfaNI RFLP. The primers used in the PCR were as follows: 5′-GACTTCAGCTTTACTCTTTGT-3′ (forward) and
5′-CTGATTGGAAACCTTATTAAG-3′ 
STATISTICAL ANALYSES
Statistical evaluation of the data was carried out using SPSS ® statistical software, version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Quantitative variables were given as mean, median, SD, minimum and maximum, whereas qualitative variables were given as numbers and percentages. The Mann-Whitney U-test was performed to compare two continuous numeric variables. For more than two continuous numeric variables, the Kruskal-Wallis test and oneway analysis of variance were performed. The χ 2 test was used for comparisons of categorical data. Genotype frequencies were tested by the χ 2 value for one degree of freedom with consideration of the Hardy-Weinberg equilibrium. A P-value of < 0.05 was considered to be statistically significant. 
Results
PATIENTS
ENOS GENE POLYMORPHISM ANALYSIS
The distribution of eNOS -786T/C gene polymorphism was 38.1% (n = 61) T/T, 52.5% (n = 84) T/C and 9.4% (n = 15) C/C. Distribution of these polymorphisms was not 
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statistically significantly different between male and female patients. When the relationships between eNOS gene polymorphism in the presence of DM, hypertension, dyslipidaemia, family history of PAD, or none, two, three, or four or more risk factors for PAD were examined, no statistically significant difference was observed in any of the groups. In addition, eNOS gene polymorphism distribution was not significantly different among patients with or without concomitant carotid artery disease. In contrast, CAD was significantly higher in patients with C allele genotypes (P = 0.019). Polymorphism distribution ratios were 22.4% (n = 11) T/T, 63.3% (n = 31) T/C and 14.3% (n = 7) C/C in patients who had concomitant CAD. In patients with PAD and with no other risk factors, 47.7% (n = 53) had the T/C genotype while 7.2% (n = 8) had the C/C genotype. Moreover, patients with CAD had significantly higher ratios of the T/C and C/C genotypes, including the C allele, (77.6%) than the T/T genotype (22.4%) (odds ratio [OR]: 2.832; 95% confidence interval [CI]: 1.313, 6.105; P = 0.007). No significant difference was observed between the distribution ratios of eNOS gene polymorphisms and lesion sites (infrainguinal: 20.0% C/C, 28.0% T/C, 27.9% T/T; suprainguinal: 66.7% C/C, 54.9% T/C, 42.6% T/T; and carotid: 13.3% C/C, 17.1% T/C, 29.5% T/T) of PAD, although the C allele was slightly more frequent in the suprainguinal lesion site.
IL-6 GENE POLYMORPHISM ANALYSIS
The distribution of IL-6 gene polymorphisms was 50.0% G/G, 35.6% G/C and 14.4% C/C and was not significantly different between male and female patients. When the relationship between IL-6 gene polymorphism in the presence of DM, hypertension, dyslipidaemia or family history of PAD was examined, there was no statistically significant difference in any of the groups. Although having none, two, three, or four or more risk factors for PAD was not significantly related to IL-6 gene polymorphism, the distribution ratios for patients having four or more risk factors (40.0% G/G, 25.0% G/C, 35.0% C/C) were significantly different towards a higher rate for the C/C genotype (P = 0.019) compared with patients with fewer than four risk factors (51.4% [n = 72] G/G, 37.1% [n = 52] G/C, 11.4% [n = 16] C/C). The odds ratio of having four or more risk factors was significantly greater with the C/C genotype than with the G/C and G/G genotypes (OR 4.173; 95% CI 1.451, 11.998; P = 0.005). On the other hand, IL-6 gene polymorphism distribution was not significantly different among patients in the presence of concomitant carotid artery disease.
Furthermore, polymorphism distribution ratios of patients with or without concomitant CAD were not significantly different from each other. No significant difference was observed between the distribution ratios of IL-6 gene polymorphisms and lesion sites (infrainguinal: 26.1% -174C/C, 26.8% -174G/C, 27.8% -174G/G; suprainguinal: 52.2% -174C/C, 53.6% -174G/C, 49.4% -174G/G; and carotid: 21.7% -174C/C, 19.6% -174G/C, 22.8% -174 G/G) of PAD.
ADMA LEVELS
The mean ADMA level was 1.13 ± 0.68 µmol/l and its distribution was not significantly different between male and female patients. The relationship between ADMA levels in the presence of DM, hypertension, dyslipidaemia, family history of PAD, concomitant CAD, concomitant carotid artery disease or risk factors for PAD was not statistically significant for any of the groups. Moreover, there was no significant AK Tuygun, M Keser, A Tuygun et al.
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difference between the ADMA levels of patients with different eNOS genotypes. Although no significant differences were observed with regards to ADMA levels between the infrainguinal, suprainguinal and carotid lesion sites, ADMA levels in the infrainguinal group were slightly higher at the femoral lesion sites.
Discussion
Known risk factors for atherosclerosis, such as age, smoking, hypertension, dyslipidaemia and DM do not completely explain the distribution of PAD in the population. On the other hand, there is evidence suggesting that eNOS and IL-6 gene polymorphisms and ADMA levels may promote atherosclerosis. 24 -31 Experiments using transgenic eNOS knockout mice have confirmed that the absence of eNOS activity results in abnormal endothelium dependent vasodilation and accelerated atherosclerosis. 32, 33 It has been determined that the T -786 ¦C mutation is associated with coronary spasm and acute myocardial infarction in the absence of organic coronary artery stenosis. 34 It has also been hypothesized that it suppresses eNOS gene transcription, reducing the production of endothelial NO and increasing the risk of atherosclerosis. In the present study, patients with C allele genotypes having concomitant PAD and CAD were examined. In accordance with the literature, 32, 34 it was found that, in patients with T/C and C/C genotypes, the frequency of artery disease was significantly higher than in patients with the T/T genotype.
Higher intracellular levels of ADMA expression in endothelial cells resurfacing an injured vessel have been observed, with the endothelial cells having an impaired endothelium-dependent vasodilation. 35 The vasoprotective factor, NOS, produces NO from the metabolism of L-arginine. For binding the enzyme, ADMA, eliminated largely by the action of DDAH, competes with L-arginine and inhibits NOS. 24 Increased plasma levels of ADMA are associated with endothelial vasodilator dysfunction in patients with vascular disease or risk factors. As suggested previously by other investigators, endogenous ADMA may influence the impaired L-arginine uptake found in essential hypertension and patients with a positive family history. 28 Although significant differences in eNOS gene polymorphism were found in the present study, no significant differences in terms of ADMA levels were noted. Inhibition of NOS could be the result of a structural change in eNOS gene product (eNOS enzyme), which may inhibit the enzyme-substrate interaction, rather than be the result of competitive inhibition. The lack of statistical significance in ADMA levels between the groups may also be due to the inadequate sample size.
There are conflicting results in previous studies correlating plasma IL-6 concentrations with the G(-174)C genotype. Some investigators found increased plasma IL-6 concentrations in patients with the GG genotype, whereas others found them with the CC genotype. 29 Plasma IL-6 concentrations have also been reported to be independent of the G(-174)C genotype. 31, 36 The present study found that patients with four or more risk factors had a significantly higher odds ratio for the C/C genotype, which shows that IL-6 gene polymorphism can be a dependent risk factor for atherosclerosis in the presence of four or more risk factors.
Although some studies have shown relationships between lesion sites and eNOS and IL-6 gene polymorphisms, 1 no such relationships were observed in the In conclusion, the present study indicated that, while ADMA levels have no effect on PAD and its risk factors, the eNOS C/C genotype may affect PAD independently and the IL-6 C/C genotype may have an additional effect in the presence of four or more risk factors.
